To Market, to Market—2019: Macromolecular Therapeutics

Agard, Nicholas J.; Dragovich, Peter S.; Beal, Allison M.; Bolger, Catherine A.; Kahn, Suzana A.; Hubbard, Brant; Lipovšek, Daša

doi:10.29200/acsmedchemrev-v55.ch28

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For organizational purposes, drugs presented in this review are categorized into the following 11 therapeutic areas: anti-infective/antibiotic, cardiovascular and hematologic, neurological (central nervous system (CNS)), dermatologic, gastrointestinal, inflammation and immunologic, metabolic, musculoskeletal, oncologic, reproductive, and respiratory drugs. Within each of these therapeutic areas, drugs are ordered alphabetically by generic name, and for each a brief overview of the relevant pharmacology or differentiating feature of the medicine and the discovery and development of the drug is provided, followed by a detailed review of the most scalable synthesis reported. Unless otherwise noted, each starting material within each scheme can be obtained from a commercial source.…”

Section: Introductionmentioning

confidence: 99%

Synthetic Approaches to the New Drugs Approved during 2019

et al. 2021

View full text Add to dashboard Cite

New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.

show abstract

Section: Introductionmentioning

confidence: 99%